Provided by Tiger Trade Technology Pte. Ltd.

RayzeBio, Inc.

62.49
0.0000
Volume:- -
Turnover:17.33M
Market Cap:3.74B
PE:-7.13
High:62.49
Open:62.49
Low:62.49
Close:62.49
52wk High:62.51
52wk Low:17.95
Shares:59.92M
Float Shares:34.82M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.7663
EPS(LYR):-19.8964
ROE:--
ROA:--
PB:6.51
PE(LYR):-3.14

Loading ...

Company Profile

Company Name:
RayzeBio, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.